Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Peripheral Nervous System Diseases 5Lymphoma 5Breast Neoplasms 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Stomatitis 2Stomach Neoplasms 2Sarcoma 2Pain 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Malnutrition 2Wilms Tumor 1Vaso-Occlusive Crises 1Squamous Cell Carcinoma of Head and Neck 1Sarcopenia 1Recurrence 1Radiation Injuries 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Oral Complications 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Malignant mesenchymal tumor 1

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Glutamine × Clear all
NCT04710290 2021-01-25

A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers

E-DA Hospital

Phase 2/3 Unknown
90 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01157039 2016-02-24

A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin

AHS Cancer Control Alberta

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡